Related Experiment Video
Updated: Feb 14, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Immune-based therapies for metastatic prostate cancer: an update
Md Kamal Hossain1, Kamrun Nahar1, Osaana Donkor2
1Vetafarm Pty Ltd, Wagga Wagga, NSW, 2650, Australia.
Abstract:
Prostate cancer (PC) is a common malignancy among elderly males and is noncurable once it becomes metastatic. In recent years, a number of antigen-delivery systems have emerged as viable and promising immunotherapeutic agents against PC. The approval of sipuleucel-T by the US FDA for the treatment of males with asymptomatic or minimally symptomatic castrate resistant PC was a landmark in cancer immunotherapy, making this the first approved immunotherapeutic. A number of vaccines are under clinical investigation, each having its own set of advantages and disadvantages. Here, we discuss the basic technologies underlying these different delivery modes, we discuss the completed and current human clinical trials, as well as the use of vaccines in combination with immune checkpoint inhibitors.
Insights
Immunotherapy offers new hope for advanced prostate cancer (PC). Sipuleucel-T is the first FDA-approved immunotherapy, with other vaccines in development for PC treatment.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Prostate cancer (PC) is a prevalent malignancy in elderly men, often incurable upon metastasis.
- Advanced PC necessitates novel therapeutic strategies beyond conventional treatments.
Purpose of the Study:
- To review emerging antigen-delivery systems for prostate cancer immunotherapy.
- To discuss the clinical landscape of PC vaccines, including completed and ongoing trials.
- To explore the potential of combining vaccines with immune checkpoint inhibitors.
Main Methods:
- Review of scientific literature on PC immunotherapies.
- Analysis of clinical trial data for PC vaccines.
- Discussion of technological advancements in antigen-delivery systems.
Main Results:
- Sipuleucel-T represents a landmark FDA-approved immunotherapy for castrate-resistant PC.
- Multiple vaccine platforms are under clinical investigation with varying efficacy and safety profiles.
- Combination strategies involving vaccines and immune checkpoint inhibitors show promise.
Conclusions:
- Antigen-delivery systems are promising immunotherapeutic agents for prostate cancer.
- Ongoing clinical trials and combination therapies are expanding treatment options for advanced PC.
- Immunotherapy, particularly with vaccines, is a rapidly evolving field in PC management.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:38What is the Immune System?
00:59Gene Therapy
01:36Humoral Immune Responses
01:26Group Therapy